T-Therapeutics is a next-generation T cell receptor (TCR) company spun off from the University of Cambridge.
T-Therapeutics has raised $32.0M in total funding. The most recent round was Series A. The last funding was announced in November 2025.
T-Therapeutics's investors include Sofinnova Partners, Cambridge Innovation Capital, Digitalis Ventures, Business Growth Fund, Sanofi Ventures.
T-Therapeutics is headquartered in Cambridge, United Kingdom.
T-Therapeutics is a next-generation T cell receptor (TCR) company spun off from the University of Cambridge.
T-Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"T-Therapeutics — Funding & Investors." VCBacked, November 13, 2025, https://www.vcbacked.co/company/t-therapeutics. Accessed July 21, 2026.
VCBacked. (2025). T-Therapeutics — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/t-therapeutics
{{cite web |title=T-Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/t-therapeutics |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated